Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.
about
Drug Development in Alzheimer's Disease: The Contribution of PET and SPECTCholinergic imaging in dementia spectrum disordersThe application of positron-emitting molecular imaging tracers in Alzheimer's disease.Clinical application of positron emission tomography for diagnosis of dementia.Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis.Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacologyCholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.In vivo visualization of donepezil binding in the brain of patients with Alzheimer's diseaseDonepezil: a review.Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.An update on the pharmacology of galantamine.In vivo imaging of neurotransmission and brain receptors in dementia.Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population.Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.The use of PET in Alzheimer disease.PET probes for imaging brain acetylcholinesterase.Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRSSyndromic approach to Parkinson's disease: role of functional imaging.In vivo evaluation of N-[18F]fluoroethylpiperidin-4ylmethyl acetate in rats compared with MP4A as a probe for measuring cerebral acetylcholinesterase activity.Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635.Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.A simple method for the detection of abnormal brain regions in Alzheimer's disease patients using [11C]MP4A: comparison with [123I]IMP SPECT.Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease.Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET.Advances in molecular imaging for the diagnosis of dementia.Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
P2860
Q26749755-918A1266-F40A-41A7-A9CB-1E1C8033A097Q26764933-26535DE8-1272-49AE-88A7-F5AC19BF58A5Q31105327-9D001FD2-67FD-4A7F-9DCA-8E8FEA8725CEQ35068733-3665B6B1-6C4D-453E-8D5A-260E24A525B5Q35486482-B4B36703-125D-4AF0-9926-786185451762Q35681597-771B0078-7FB7-4849-8132-F1224063B4E0Q35781558-F9BFD754-02D7-4155-A5CB-7CF6FECA2631Q36097637-C0BA4F63-E3E3-4522-A393-16AD27CA21A6Q36475090-DE714AAA-4034-4200-9586-848E5F6D093DQ36536430-D0FC35D6-E66B-4718-BFFA-94256E93F567Q36544994-7E7C590E-4E98-49A9-8C8E-3A4597E6FC1CQ36743706-03E39C6E-3F74-43AB-B4D6-CBF99F3BD29FQ37016107-33931E44-1FF6-4C2B-B9D6-B6A173FDF1D9Q37124915-3973DB11-FB09-48C7-9FAF-555E87DDC15AQ37129594-267970C7-C86E-4041-984F-49AD71EF5840Q37222701-A8625D68-945E-457B-A60F-89EE80360E23Q37511433-C1441B78-E861-4FDA-AAEC-F7999886B1B5Q37688880-4AA23C99-02C3-4415-95C9-38FF33A4E8B5Q38166972-A1B15D87-0B3F-489B-91DF-CE7D4C71299CQ41888068-9D486268-1B6E-45C3-9763-00F81B5194A1Q41979984-F2ED875F-25EC-47F6-854A-10C4AAFD46AAQ43253662-134DB879-474D-4F98-98DC-0CBB28E6D43DQ44347231-F7772D16-E666-4073-AF42-6A6F6022F6D9Q44894391-AFFF4189-0B2F-4898-9FD9-6C303A343EB6Q44962933-E6ACCD4F-64C3-429C-9885-3B80CA47B769Q45191263-8FFC296F-D27E-41B6-A245-BB71AE952AB2Q45663984-07E380F7-2EF6-474E-9F76-27F4C0973A71Q46513880-DCEF18FB-47CF-43E1-B32E-71DD47493CF5Q48420736-3A61815B-D242-45DF-99B5-98E303B5308BQ48500758-A9312FF3-7055-46D7-8BF5-30B9541D8474
P2860
Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of donepezil on brain a ...... ients with AD measured by PET.
@ast
Effect of donepezil on brain a ...... ients with AD measured by PET.
@en
type
label
Effect of donepezil on brain a ...... ients with AD measured by PET.
@ast
Effect of donepezil on brain a ...... ients with AD measured by PET.
@en
prefLabel
Effect of donepezil on brain a ...... ients with AD measured by PET.
@ast
Effect of donepezil on brain a ...... ients with AD measured by PET.
@en
P2093
P356
P1433
P1476
Effect of donepezil on brain a ...... ients with AD measured by PET.
@en
P2093
Nagatsuka S
Shinotoh H
P304
P356
10.1212/WNL.56.3.408
P407
P577
2001-02-01T00:00:00Z